Acute effect of proprotein convertase subtilisin/kexin type 9 inhibitor on oxidized low-density lipoprotein and lipid profile in patients at cardiovascular risk

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of potent lipid-lowering drugs. Oxidized low-density lipoprotein (ox-LDL) is the key pathogenic factor leading to atherosclerosis. However, its effect on ox-LDL levels has not been clinically reported. The clinical data...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yiming, Sun, Minni, Li, Ran, Dou, Min, Dong, Haozhe, Xue, Liqi, Sun, Guoju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636578/
https://www.ncbi.nlm.nih.gov/pubmed/37970546
http://dx.doi.org/10.3164/jcbn.23-45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636578/
https://www.ncbi.nlm.nih.gov/pubmed/37970546
http://dx.doi.org/10.3164/jcbn.23-45

Ejemplares similares